Enoxaparin-Induced DRESS Syndrome

Ronceray, S.; Dinulescu, M.; Gall, François Le; Polard, Élisabeth; Dupuy, Alain; Adamski, H.

doi:10.1159/000345096

Cited by 24 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antihypertensives-spironolactone [21] Hypouricemics-allopurinol Anticoagulants-acenocoumarol, enoxaparin [22] Hypoglycemic agents-sitagliptin [23] Antiosteoporotic agents-strontium ranelate [24] tions via haptenation. For example, this has been described with CBZ and generation of reactive arene oxide metabolites.…”

Section: Statins-atorvastatinmentioning

confidence: 99%

Eosinophilic Drug Allergy

Kuruvilla

Khan

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

While peripheral or tissue eosinophilia may certainly characterize drug eruptions, this feature is hardly pathognomonic for a medication-induced etiology. While delayed drug hypersensitivity reactions with prominent eosinophilic recruitment have been typically classified as type IVb reactions, their pathophysiology is now known to be more complex. Eosinophilic drug reactions have a diversity of presentations and may be benign and self-limited to severe and life-threatening. The extent of clinical involvement is also heterogeneous, ranging from isolated peripheral eosinophilia or single organ involvement (most often the skin and lung) to systemic disease affecting multiple organs, classically exemplified by drug-reaction with eosinophilia and systemic symptoms (DRESS). The spectrum of implicated medications in the causation of DRESS is ever expanding, and multiple factors including drug metabolites, specific HLA alleles, herpes viruses, and immune system activation have been implicated in pathogenesis. Due to this complex interplay of various factors, diagnostic workup in terms of skin and laboratory testing has not been validated. Similarly, the lack of controlled trials limits treatment options. This review also describes other localized as well as systemic manifestations of eosinophilic disease induced by various medication classes, including their individual pathophysiology, diagnosis, and management. Given the multitude of clinical patterns associated with eosinophilic drug allergy, the diagnosis can be challenging. Considerable deficits in our knowledge of these presentations remain, but the potential for severe reactions should be borne in mind in order to facilitate diagnosis and institute appropriate management.

show abstract

Section: Statins-atorvastatinmentioning

confidence: 99%

Eosinophilic Drug Allergy

Kuruvilla

Khan

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

show abstract

“…Rarely, reports of bullous hemorrhagic dermatosis and drug reaction with eosinophilia and systemic symptoms syndrome are described. 2,3 To our knowledge no cases of enoxaparin-induced erythema multiforme have been described. Erythema multiforme is an acute mucocutaneous condition that classically presents with targetoid lesions.…”

Section: Discussionmentioning

confidence: 96%

“…A less common but recognized risk is heparin‐induced thrombocytopenia resulting from antibodies against heparin/platelet factor‐4. Rarely, reports of bullous hemorrhagic dermatosis and drug reaction with eosinophilia and systemic symptoms syndrome are described . To our knowledge no cases of enoxaparin‐induced erythema multiforme have been described.…”

Section: Discussionmentioning

confidence: 99%

Postpartum eruption of enoxaparin‐induced erythema multiforme

Schadler

Joyce

Haugen

2018

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…However, fondaparinux is generally well tolerated in patients who react to LMWHs 194 . Heparin may induce DRESS 198 and SJS 199 …”

Section: Anti‐coagulant and Anti‐aggregant Drugs Used For Coagulopathymentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Gelincik

Brockow

Çelik

et al. 2020

Allergy

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID‐19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off‐label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off‐label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

show abstract

Enoxaparin-Induced DRESS Syndrome

Cited by 24 publications

References 8 publications

Eosinophilic Drug Allergy

Eosinophilic Drug Allergy

Postpartum eruption of enoxaparin‐induced erythema multiforme

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Contact Info

Product

Resources

About